Cargando…

Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis

OBJECTIVE: Previous studies have controversial results about the prognostic role of soluble suppression of tumorigenicity 2 (sST2) in chronic kidney disease (CKD). Therefore, we conduct this meta-analysis to access the association between sST2 and all-cause mortality, cardiovascular disease (CVD) mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Guangying, Huang, Aoran, Huang, Xin, Xu, Tianhua, Yao, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857877/ https://www.ncbi.nlm.nih.gov/pubmed/33574967 http://dx.doi.org/10.1155/2021/8881393

Ejemplares similares

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure
por: Sun, Yanxiang, et al.
Publicado: (2022)

Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis
por: Gu, Linlin, et al.
Publicado: (2019)

Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis
por: Shi, Yujiao, et al.
Publicado: (2022)

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
por: Yang, Hyun Suk, et al.
Publicado: (2016)

Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
por: Gül, İbrahim, et al.
Publicado: (2017)

Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction
por: Cui, Yameng, et al.
Publicado: (2018)

Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review
por: Ahmadzadeh, Koohyar, et al.
Publicado: (2023)

Effect of local anti-vascular endothelial growth factor therapy to prevent the formation of stenosis in outflow vein in arteriovenous fistula
por: Huang, Xin, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
por: Öncel, Can Ramazan
Publicado: (2018)

Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
por: Iannazzo, Francesco, et al.
Publicado: (2022)

Prognostic Utility of Soluble Suppression of Tumorigenicity 2 level as a Predictor of Clinical Outcomes in Incident Hemodialysis Patients
por: Seo, Suk Min, et al.
Publicado: (2018)

Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity‐2
por: Gerber, Yariv, et al.
Publicado: (2017)

A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension
por: Luk, King Sum, et al.
Publicado: (2017)

Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study
por: Wang, Zhiyu, et al.
Publicado: (2020)

Soluble suppression of tumorigenicity 2 associated with fulminant myocarditis in children: A retrospective observational study
por: Hou, Wenquan, et al.
Publicado: (2023)

Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure
por: Alladina, Jehan W., et al.
Publicado: (2021)

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis
por: Liu, Niannian, et al.
Publicado: (2020)

Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis
por: Zhang, Yan, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with atrial fibrillation detected after stroke: A retrospective study
por: Hou, Wenquan, et al.
Publicado: (2023)

Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation
por: Tan, Ruopeng, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study
por: Rezar, Richard, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes
por: Moon, Jong Joo, et al.
Publicado: (2023)

Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction
por: Kim, Min, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis
por: Ip, Christina, et al.
Publicado: (2021)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Deletion of soluble epoxide hydrolase suppressed chronic kidney disease-related vascular calcification by restoring Sirtuin 3 expression
por: He, Wanbing, et al.
Publicado: (2021)

The prognostic value of soluble Klotho in patients with haemodialysis: a systematic review and meta-analysis
por: Liu, Qi-Feng, et al.
Publicado: (2020)

Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range
por: Hasan, Amal, et al.
Publicado: (2020)

Prognostic Role of High-sensitivity Cardiac Troponin I and Soluble Suppression of Tumorigenicity-2 in Surgical Intensive Care Unit Patients Undergoing Non-cardiac Surgery
por: Yang, Hyun Suk, et al.
Publicado: (2018)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Correlation between Levels of Serum Lipoprotein-Associated Phospholipase A2 and Soluble Suppression of Tumorigenicity 2 and Condition of Acute Heart Failure Patients and Their Predictive Value for Prognosis
por: Zhang, Jinjin, et al.
Publicado: (2021)

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
por: Magro, Fernando, et al.
Publicado: (2019)

Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
por: Kim, Hanah, et al.
Publicado: (2017)

Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect
por: Pratama, Reza S., et al.
Publicado: (2020)

The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy
por: Iqbal, Mohammad, et al.
Publicado: (2023)

PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells
por: Huang, Wenqiang, et al.
Publicado: (2016)

Prevalence and prognostic value of malnutrition in patients with acute coronary syndrome and chronic kidney disease
por: Ni, Weicheng, et al.
Publicado: (2023)

Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis
por: Sun, Yiting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vjer5b73e3prg2pl3071ccugsr